



ASX MARKET ANNOUNCEMENT

Clinical Research Corporation - Contract Update

25th May 2015

iQ3Corp Ltd (ASX:IQ3) is pleased to announce that a previously ratified agreement, which mandated iQ3Corp to act as lead manager, corporate advisor and to capital raise for Clinical Research Corporation Pty Ltd (CRC) pre-Initial Public Offering (IPO), has now been extended to cover the IPO.

More specifically, iQ3 will now be:

- acting as lead manager and corporate advisor for the IPO
- conducting the IPO capital raising
- managing the underwriting of the offer

iQ3Corp's CEO, Dr. George Syrmalis said, "The nature of the business of CRC, goes well beyond a typical CRO and extends a solid and crystal clear value proposition to the Medical Affairs business units within the Australian Bio-pharmaceutical industry. These are exciting times for Australian life science companies."

For more information, please feel free to contact the iQ3Corp Investor Relations Team.

Email:

investor.relations@iq3corp.com

Phone:

+61 2 8239 5400

About iQ3Corp Limited:

iQ3Corp is a specialised life science corporate finance and advisory firm bridging capital with science to create the medicines of the future.

Disclaimer

Subject to any continuing obligations under the laws of the Commonwealth of Australia or the ASX listing rules, iQ3Corp Ltd (iQ3Corp or the Company) disclaims any perceived intent or undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events or results or otherwise. Expressions such as 'believe', 'expect', 'anticipate', 'indicate', 'contemplate', 'target', 'plan', 'intends', 'continue', 'budget', 'estimate', 'may', 'will', 'schedule' and similar expressions identify forward-looking statements. The following cautionary statements qualify all forward-looking statements made in this announcement. In particular, the direction and strategies adopted by iQ3Corp and detailed in this announcement represents the Company's strategic planning and decision-

iQ3Corp. Ltd
ABN: 63 160 238 282
iq3corp.com

Levels 3 & 6
222 Clarence Street
Sydney NSW 2000

Tel: +61 2 8239 5400
Fax: +61 2 8362 9547
info@iq3corp.com



making practices and are based on current expectations. iQ3Corp's business is subject to uncertainties, risks and contingencies, many of which are outside the control of, and are presently unknown to the Company, and could cause the actual conduct, results, performance or achievements of iQ3Corp to vary in a material way from those expressed or implied in this announcement. Investors are cautioned that forward-looking statements are not guarantees of future performance or outcomes, and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. Additional information concerning iQ3Corp's business, its associated risks and operations can be found in its periodic announcements to ASX.